Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01185 (vasopressin)
 23,126 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The direct action of arginine-vasopressin (AVP) and its deamino-D-arginine analogue (DDAVP) on renin release (RR) has been studied in isolated rat kidneys perfused with an electrolyte solution at constant pressure in a single-pass system. AVP and DDAVP infused at various concentrations (80 to 2100 pg/ml and 80 to 8700 pg/ml, respectively) reduced volume and increased osmolality of urine in a dose-dependent way. High doses of AVP reduced renal perfusate flow and glomerular filtration rate while DDAVP had no effect on renal haemodynamics. When vasoconstrictor doses of AVP or high concentrations of DDAVP were infused, "basal" RR remained unchanged. However, when RR had been stimulated by infusion of isoproterenol, vasoconstrictor doses of AVP as well as high doses of DDAVP which did not increase renal vascular resistance diminished RR by about 30% (P less than 0.01, and P less than 0.05, respectively). These results suggest that the inhibition of RR by vasopressin is not related to its vasoconstrictor action.
 ...
PMID:Effects of vasopressin and its deamino-D-arginine analogue on renin release in the isolated perfused rat kidney. 56 83

Twenty children with diabetes inspidus, 19 children and adolescents and one baby of 2 months, were treated with DDAVP. The drug was very effective, the average urine volume being 1.7 L/24 hours. The control of the diuresis in the baby was very satisfactory. There were no secondary effects and the only episode of water intoxication occurred in a girl with corticosteroid deficiency which was not well controlled. The effects of this drug are discussed in the light of the biochemistry and pharmacology and the activity compared with that of Lysine vasopressin (LVP). Plasma levels of DDAVP and LVP showed that DDAVP persists for longer which may explain its greater potency and duration of action.
 ...
PMID:[Treatment of ADP responsive diabetes insipidus in children with DDAVP (1-desamino-8-D-arginine-vasopressin)]. 61 Jun 62

We have investigated the effect of indomethacin and DDAVP on water excretion in a patient with familial Bartter's syndrome in whom urinary concentration was impaired during ad libitum fluid intake without any decrease in maximal concentrating ability. In response to indomethacin urine osmolality and free water reabsorption increased, simultaneously with the decrease in the excretion of prostaglandin E2. The indomethacin induced improvement was however less than that obtained after DDAVP with or without indomethacin. The results can be interpreted on the basis of either a direct "vasopressin-like" action of indomethacin or abolishment of the peripheral vasopressin--prostaglandin interaction. The clinical implication is that the theoretical possibility of indomethacin-induced inappropriate ADH syndrome should be borne in mind when a patient is treated with this drug on a long term basis.
 ...
PMID:Pharmacologic studies in Bartter's syndrome: effect of DDAVP and indomethacin on renal concentrating operation. Part II. 63 67

Defective fibrinolytic activity is often a contributory factor in deep venous thrombosis. A family with a high incidence of venous thrombosis in association with such a defect is presented. Of 13 family members who had had thrombosis, 12 showed a defective capacity to release fibrinolytic activity from vessel wall after venous occlusion and/or infusion of DDAVP, a vasopressin derivative. The fibrinolytic activator activity of the vessel wall was normal in all cases. This seems to be the first family in which there is evidence of an inherited abnormal fibrinolytic activity.
 ...
PMID:A family with thromboembolic disease associated with deficient fibrinolytic activity in vessel wall. 66 14

Classical dehydration and vasopressin tests for estimation of renal concentrating capacity are inconvenient and sometimes hazardous. We attempted to use the new potent long-lasting synthetic vasopressin analogue (DDAVP) which has no side effects for testing renal concentrating capacity in adults. Four groups of persons were investigated: in Groups 1 and 3, 11 and another 11 healthy subjects; in Group 2, seven convalescent older patients; and in Group 4, 11 patients with pituitary diabetes insipidus (DI). Groups 1 and 2 were investigated during 15 hours' dehydration; DDAVP was given at the end of the 12th hour intravenously (4 microgram) or intransally (80 micron). DDAVP failed to influence strikingly the normal increase in renal concentration induced by lengthening the dehydration from 12 hours to 15 hours. On the other hand, in patients with DI under prolonged treatment as well as in healthy individuals (Group 3), a dose of 20 to 40 microgram of DDAVP administered intranasally induced (at least) as high peak urine osmolality during ad libitum fluid intake as was induced in normal subjects (Group 1) by 12 hours' dehydration alone. In patients with DI the maximal effect of DDAVP obtained during ad libitum fluid intake could be further enhanced by added dehydration. Urine sampling for osmolality three hours after a single intranasal dose of 40 microgram DDAVP during ad libitum fluid intake is a new safe, simple and convenient test for rapid estimation of concentrating ability.
 ...
PMID:1-desamino-8-D-arginine vasopressin (DDAVP) concentration test. 66 11

Modification of the natural vasopressin molecule to form desmopressin acetate (DDAVP) resulted in a compound with prolonged antidiuretic activity and virtual elimination of vasopressor activity. Twenty-one patients with central diabetes insipidus who ranged in age from 3 to 68 years were treated with DDAVP, which was administered intranasally in a dosage ranging from 10 microgram every 12 hours to 20 microgram every eight hours. Effective control of symptoms was obtained in all cases. There were no consequential toxic effects. As previously reported, DDAVP appears to be the preferred drug for the management of central diabetes insipidus. Biochemical alteration of hormones may enhance desired therapeutic activity and eliminate toxic effects. The development of DDAVP is an example of the potential for development of useful therapeutic peptides.
 ...
PMID:Treatment of central diabetes insipidus in adults and children with desmopressin. 68 29

The effects of a synthetic analogue of vasopressin, DDAVP (1-deamino-8-D-arginine vasopressin) were investigated in 98 patients with cranial diabetes insipidus. In all patients, intranasal administration of DDAVP one to three times daily, usually twice daily, was found to be satisfactory in the control of diabetes insipidus. Thus, by DDAVP administration, daily urinary volume changed from 3520 +/- 2150 ml to 1620 +/- 830 ml (mean +/- SD), and urinary osmolarity changed from 126 +/- 75 mOsm/kgH2O to 446 +/- 194 mOsm/kgH2O (mean +/- SD). A daily dose of DDAVP ranged from 2.0 to 20 microgram in children (average dose 12.8 microgram), while 10 to 20 microgram of DDAVP was usually required in adult patients (average dose 14.2 microgram). No serious side effects have been observed. It is concluded that DDAVP is safe and effective in the treatment of cranial diabetes insipidus.
 ...
PMID:[The treatment of patients with diabetes insipidus by a synthetic analogue of vasopressin, DDAVP (author's transl)]. 68 12

Desmopressin acetate is a synthetic vasopressin analogue administered by the intranasal route. It is long-acting and well tolerated and may be the agent of choice for treating central diabetes insipidus.
 ...
PMID:Evaluation of a new antidiuretic agent, desmopressin acetate (DDAVP). 69 Dec 4

A synthetic vasopressin analog, 1-desamino-8D-arginine vasopressin (DDAVP also known as desmopressin), was found to be highly effective in the treatment of seven children and one adult with vasopressin-sensitive diabetes insipidus. The average duration of action of DDAVP was 10 to 11 hours, and with proper adjustment of dose, the subjects were able to control their symptoms satisfactorily with one or two inhalations daily. The youngest child in whom adequate control was achieved was 2 years of age. All subjects found the use of intranasal DDAVP superior to other forms of therapy, and none experienced any known side-effects after six months of treatment. All subjects in this study are currently using 2.5 mug to 10 mug of DDAVP once or twice daily.
 ...
PMID:Vasopressin analog DDAVP in the treatment of diabetes insipidus. 76 13

The antidiuretic effects of graded intravenous and intranasal doses of a new vasopressin analogue (DDAVP) were investigated in two groups of patients with pituitary diabetes insipidus. In the first group, three patients with a high requirement of maintenance doses of peroral anti-diuretic drugs were included; and in the second group, ten patients with a normal (usual) requirement were included. Comparing the antidiuretic responses during 24-hour collection periods, DDAVP, on a microgram basis, was less effective in the "high peroral-dose requirement" patients. The duration of action of single intravenous doses (0.04-24 micrograms) of DDAVP was significantly shortened in the "high peroral-dose requirement" group. However, comparing the peak responses induced by increasing doses of DDAVP in the two groups, there was no demonstrable diminution in the anti-diuretic ability of DDAVP in the "high peroral-dose requirement" patients. Although the possibility of a smaller remnant reserve of ADH was also considered, shortened duration of action ot DDAVP suggests more probably enhanced metabolic breakdown of vasopressin in "high peroral-dose requirement" patients.
 ...
PMID:Shortened duration of action of 1-deamino-8-D-arginine vasopressin (DDAVP) in patients with diabetes insipidus requiring high doses of peroral antidiuretic drugs. 78 14


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>